Please login to the form below
Gruenenthal
This page shows the latest Gruenenthal news and features for those working in and with pharma, biotech and healthcare.
AZ divests European rights for cholesterol med Crestor to Grünenthal
Grünenthal will pay up to $350m for the rights
Latest news
-
Sanofi’s rare blood disorder drug Cablivi set for European approval
In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.
-
Europe's public-private alliance targets pain management
Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area
-
Pharma's first 'performance marketing' agency launched
Founded by Matt Lowe, performance.io aims to redefine online performance
-
Lundbeck partners with 23andMe on first-of-its-kind study
Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys
-
Grünenthal buys Zomig rights as AZ slimming drive continues
Acquires global rights outside Japan to the migraine drug
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Pursuing better outcomes for people with pain
Using the patient’s voice to change how we conduct R&D
-
Grünenthal's relentless pursuit of relief
New CEO Gabriel Baertschi on putting pain in the crosshairs of innovation
-
Deal Watch June 2016
Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity
-
Pharma deals in June 2015
Allergan's $2.1bn acquisition of Kythera tops this month's deals
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
GPI appoints commercial director
Alan Stewart joins the life science management consultancy's executive team
-
AZ’s Gabriel Baertschi joins Grünenthal as CEO
He also becomes chairman of the corporate executive board
-
New CEO for Grayling Germany
Frank Schönrock joins from Grünenthal
-
Oscar Ferenczi joins Grünenthal from Sandoz
Will lead German pharma company's Latin American expansion plans
-
Grünenthal's Harald Stock joins OvaScience board
Provides European expertise as fertility company looks to expand beyond US
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we help life science companies gain the capabilities to employ the power of
-
Dramatic shifts in pharma drive patient needs to trump all – including C-Suite authority
eyeforpharma, London (January, 19, 2015): According to LEO Pharma, Ipsen and Grünenthal driving patient-centric leadership has become priority as the patient voice shapes the future for the pharmaceutical industry. Speaking ahead of the
-
Apps & Digital Resources vie for top honour at eyeforpharma Barcelona Awards
Two thirds of the finalists for the ‘Most Valuable Patient Initiative’ in the 2015 eyeforpharma Barcelona Awards have used interactive digital resources or mobile applications to engage with the patient; a tell-tale sign of the dominance of
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
